drugset

drugset / Trial / NCT01772810

Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI

NCT01772810 ↗

Phase 1 Unknown 8 enrolled Neuralstem Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a safety study of human spinal cord-derived neural stem cell (HSSC) transplantation for the treatment of chronic spinal cord injury.

Timeline

Start: 2014-08
Primary completion: 2018-07
Completion: 2022-12

Publications

Martin JR, Cleary D, Abraham ME, Mendoza M, Cabrera B, Jamieson C, Marsala M, Ciacci JD. Long-term clinical and safety outcomes from a single-site phase 1 study of neural stem cell transplantation for chronic thoracic spinal cord injury. Cell Rep Med. 2024 Dec 17;5(12):101841. doi: 10.1016/j.xcrm.2024.101841. Epub 2024 Dec 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NSI-566	Cell therapy	—	—

Indications